©The Author(s) 2022.
World J Gastrointest Oncol. Apr 15, 2022; 14(4): 920-934
Published online Apr 15, 2022. doi: 10.4251/wjgo.v14.i4.920
Published online Apr 15, 2022. doi: 10.4251/wjgo.v14.i4.920
Table 3 Treatment-related adverse event
| Adverse event | Number of patients (n = 30), n (%) | ||
| Any grade | Grade 1-2 | Grade 3 | |
| Any event | 17 (56.7) | 13 (43.3) | 4 (13.3) |
| Hand-foot syndrome | 10 (33.3) | 8 (26.7) | 2 (6.7) |
| Hypertension | 7 (23.3) | 7 (23.3) | 0 |
| Malaise | 6 (20.0) | 6 (20.0) | 0 |
| Gastrointestinal reaction | 5 (16.7) | 5 (16.7) | 0 |
| Transaminase elevation | 4 (13.3) | 3 (10.0) | 1 (3.3) |
| Diarrhea | 3 (10.0) | 3 (10.0) | 0 |
| Abnormal capillary proliferation | 2 (6.7) | 1 (3.3) | 1 (3.3) |
| Hypothyroidism | 2 (6.7) | 2 (6.7) | 0 |
| Proteinuria | 2 (6.7) | 2 (6.7) | 0 |
| Rash | 2 (6.7) | 2 (6.7) | 0 |
| Thrombocytopenia | 2 (6.7) | 2 (6.7) | 0 |
| Anemia | 1 (3.3) | 1 (3.3) | 0 |
| Myocardial enzyme elevation | 1 (3.3) | 1 (3.3) | 0 |
| Oral mucositis | 1 (3.3) | 1 (3.3) | 0 |
| Leukopenia/neutropenia | 0 | 0 | 0 |
- Citation: Xu YJ, Zhang P, Hu JL, Liang H, Zhu YY, Cui Y, Niu P, Xu M, Liu MY. Regorafenib combined with programmed cell death-1 inhibitor against refractory colorectal cancer and the platelet-to-lymphocyte ratio’s prediction on effectiveness. World J Gastrointest Oncol 2022; 14(4): 920-934
- URL: https://www.wjgnet.com/1948-5204/full/v14/i4/920.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v14.i4.920